60 Degrees Pharmaceuticals Announces Positive Babesiosis Treatment Results in First Patient Study

60 Degrees Pharmaceuticals has announced that the first patient in their relapsing babesiosis study has tested negative for babesiosis after treatment with tafenoquine. The study aims to confirm the high cure rate of tafenoquine in immunosuppressed patients with relapsing babesiosis. The Company has submitted a request for Breakthrough Therapy Designation and plans to request a Type B meeting with the FDA in early 2026 to discuss the requirements for a supplementary New Drug Application.